CRON Quote, Financials, Valuation and Earnings

Edesa Biotech has a net margin of 24.37% compared to Cronos Group's net margin of --. Cronos Group's return on equity of 3.76% beat Edesa Biotech's return on equity of --.

Cronos Group has a consensus price target of $1.89, signalling upside risk potential of 1.94%. On the other hand Edesa Biotech has an analysts' consensus of $19.00 which suggests that it could grow by 708.51%. Given that Edesa Biotech has higher upside potential than Cronos Group, analysts believe Edesa Biotech is more attractive than Cronos Group.

Cronos Group has a beta of 1.018, which suggesting that the stock is 1.754% more volatile than S&P 500. In comparison Edesa Biotech has a beta of 0.603, suggesting its less volatile than the S&P 500 by 39.713%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edesa Biotech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Edesa Biotech pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $30.3M, which are larger than Edesa Biotech quarterly revenues of --. Cronos Group's net income of $43.7M is higher than Edesa Biotech's net income of -$1.6M. Notably, Cronos Group's price-to-earnings ratio is 16.82x while Edesa Biotech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.02x versus 23.24x for Edesa Biotech. Usually stocks with elevated PS ratios are considered overvalued.

Lexaria Bioscience has a net margin of 24.37% compared to Cronos Group's net margin of -1559.32%. Cronos Group's return on equity of 3.76% beat Lexaria Bioscience's return on equity of -118.15%.

Cronos Group has a consensus price target of $1.89, signalling upside risk potential of 1.94%. On the other hand Lexaria Bioscience has an analysts' consensus of $7.00 which suggests that it could grow by 314.2%. Given that Lexaria Bioscience has higher upside potential than Cronos Group, analysts believe Lexaria Bioscience is more attractive than Cronos Group.

Cronos Group has a beta of 1.018, which suggesting that the stock is 1.754% more volatile than S&P 500. In comparison Lexaria Bioscience has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.5%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lexaria Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Lexaria Bioscience pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $30.3M, which are larger than Lexaria Bioscience quarterly revenues of $174K. Cronos Group's net income of $43.7M is higher than Lexaria Bioscience's net income of -$2.7M. Notably, Cronos Group's price-to-earnings ratio is 16.82x while Lexaria Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.02x versus 51.21x for Lexaria Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Tilray Brands has a net margin of 24.37% compared to Cronos Group's net margin of -424.93%. Cronos Group's return on equity of 3.76% beat Tilray Brands's return on equity of -28.79%.

Cronos Group has a consensus price target of $1.89, signalling upside risk potential of 1.94%. On the other hand Tilray Brands has an analysts' consensus of $1.31 which suggests that it could grow by 165.32%. Given that Tilray Brands has higher upside potential than Cronos Group, analysts believe Tilray Brands is more attractive than Cronos Group.

Cronos Group has a beta of 1.018, which suggesting that the stock is 1.754% more volatile than S&P 500. In comparison Tilray Brands has a beta of 1.885, suggesting its more volatile than the S&P 500 by 88.482%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tilray Brands offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Tilray Brands pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $30.3M, which are smaller than Tilray Brands quarterly revenues of $185.8M. Cronos Group's net income of $43.7M is higher than Tilray Brands's net income of -$789.4M. Notably, Cronos Group's price-to-earnings ratio is 16.82x while Tilray Brands's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.02x versus 0.51x for Tilray Brands. Usually stocks with elevated PS ratios are considered overvalued.

Xenon Pharmaceuticals has a net margin of 24.37% compared to Cronos Group's net margin of --. Cronos Group's return on equity of 3.76% beat Xenon Pharmaceuticals's return on equity of --.

Cronos Group has a consensus price target of $1.89, signalling upside risk potential of 1.94%. On the other hand Xenon Pharmaceuticals has an analysts' consensus of $57.31 which suggests that it could grow by 50.03%. Given that Xenon Pharmaceuticals has higher upside potential than Cronos Group, analysts believe Xenon Pharmaceuticals is more attractive than Cronos Group.

Cronos Group has a beta of 1.018, which suggesting that the stock is 1.754% more volatile than S&P 500. In comparison Xenon Pharmaceuticals has a beta of 1.212, suggesting its more volatile than the S&P 500 by 21.24%.

Cronos Group has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xenon Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cronos Group pays -- of its earnings as a dividend. Xenon Pharmaceuticals pays out -- of its earnings as a dividend.

Cronos Group quarterly revenues are $30.3M, which are larger than Xenon Pharmaceuticals quarterly revenues of --. Cronos Group's net income of $43.7M is higher than Xenon Pharmaceuticals's net income of -$65.7M. Notably, Cronos Group's price-to-earnings ratio is 16.82x while Xenon Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cronos Group is 6.02x versus 225.92x for Xenon Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.